BioCentury | Aug 13, 2020
Product Development

BMS heeds BIO’s call to ‘walk the talk’

A week after BIO unveiled its BIOEquality initiative, BMS said it is preparing to invest $300 million to increase diversity in clinical trials of its therapies and the representation of Blacks and Latinos at all...
BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

NASDAQ debuts by Syncona gene therapy company Freeline and Checkmate, a cancer company co-founded by Art Krieg, pushed the year’s IPO haul to $14.7 billion, more than double the amount raised over the same period...
BioCentury | Aug 7, 2020
Deals

Survey: sweet spots and vulnerabilities for dealmaking in the COVID era

Heading into the second half of the year with cautious optimism, drug developers see opportunities for dealmaking created by COVID-19, as well as challenges. If their predictions are right, infectious deals could surpass cancer transactions....
BioCentury | Aug 6, 2020
Politics, Policy & Law

BIO challenging its members to walk the talk on social justice

Outrage over the killing of George Floyd prompted biopharma leaders and companies to look up from their work developing molecules to consider their companies’ roles in advancing social justice. Now BIO is challenging its members...
BioCentury | Aug 4, 2020
Finance

Interest in protein degradation runs hot as Kymera files for IPO

Atlas-backed Kymera has at least one comparator among preclinical protein degradation companies as it seeks a NASDAQ listing -- and it could soon be followed by another company in the same category. A regulatory filing...
BioCentury | Jul 29, 2020
Emerging Company Profile

Bright Peak synthesizing proteins like they’re small molecules with $35M from Versant

Bright Peak thinks its medicinal chemistry approach to protein design will make its synthetic cytokines stand out from the pack. Built by Versant Ventures’ Basel-based Ridgeline outpost with technology licensed from ETH Zurich, Bright Peak...
BioCentury | Jul 28, 2020
Emerging Company Profile

Frazier, Marcadia founders reunite for rare endocrine diseases in MBX’s $34.6M A round

Kent Hawryluk and Richard DiMarchi are following up on the first two companies they formed together, diabetes-focused Marcadia and MB2, with rare endocrine diseases play MBX Biosciences. Frazier, which led Marcadia Biotech Inc.’s series A...
BioCentury | Jul 22, 2020
Emerging Company Profile

Deep Longevity: Insilico spinout clocks biological age

Insilico spinout Deep Longevity came out of stealth last week with 17 sets of biomarkers, dubbed aging clocks, designed to measure the rate of aging that could be applied to measure treatment efficacy in clinical...
BioCentury | Jul 22, 2020
Product Development

Pharma survey: COVID-19 foreshadows a change in how business is done

As pharmas grapple with how to return to work, employees are being given the upper hand in deciding when and how to do so. The result could preface a transformation to a semi-virtual office structure,...
BioCentury | Jul 22, 2020
Emerging Company Profile

Jnana goes after metabolism-mediating proteins, gains Roche as partner

Jnana is developing small molecules against a relatively untapped class of proteins -- solute carriers -- to modulate cell metabolism. On Tuesday, the biotech closed its first deal with a large biopharma, partnering with Roche...
Items per page:
1 - 10 of 6276
BioCentury | Aug 13, 2020
Product Development

BMS heeds BIO’s call to ‘walk the talk’

A week after BIO unveiled its BIOEquality initiative, BMS said it is preparing to invest $300 million to increase diversity in clinical trials of its therapies and the representation of Blacks and Latinos at all...
BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

NASDAQ debuts by Syncona gene therapy company Freeline and Checkmate, a cancer company co-founded by Art Krieg, pushed the year’s IPO haul to $14.7 billion, more than double the amount raised over the same period...
BioCentury | Aug 7, 2020
Deals

Survey: sweet spots and vulnerabilities for dealmaking in the COVID era

Heading into the second half of the year with cautious optimism, drug developers see opportunities for dealmaking created by COVID-19, as well as challenges. If their predictions are right, infectious deals could surpass cancer transactions....
BioCentury | Aug 6, 2020
Politics, Policy & Law

BIO challenging its members to walk the talk on social justice

Outrage over the killing of George Floyd prompted biopharma leaders and companies to look up from their work developing molecules to consider their companies’ roles in advancing social justice. Now BIO is challenging its members...
BioCentury | Aug 4, 2020
Finance

Interest in protein degradation runs hot as Kymera files for IPO

Atlas-backed Kymera has at least one comparator among preclinical protein degradation companies as it seeks a NASDAQ listing -- and it could soon be followed by another company in the same category. A regulatory filing...
BioCentury | Jul 29, 2020
Emerging Company Profile

Bright Peak synthesizing proteins like they’re small molecules with $35M from Versant

Bright Peak thinks its medicinal chemistry approach to protein design will make its synthetic cytokines stand out from the pack. Built by Versant Ventures’ Basel-based Ridgeline outpost with technology licensed from ETH Zurich, Bright Peak...
BioCentury | Jul 28, 2020
Emerging Company Profile

Frazier, Marcadia founders reunite for rare endocrine diseases in MBX’s $34.6M A round

Kent Hawryluk and Richard DiMarchi are following up on the first two companies they formed together, diabetes-focused Marcadia and MB2, with rare endocrine diseases play MBX Biosciences. Frazier, which led Marcadia Biotech Inc.’s series A...
BioCentury | Jul 22, 2020
Emerging Company Profile

Deep Longevity: Insilico spinout clocks biological age

Insilico spinout Deep Longevity came out of stealth last week with 17 sets of biomarkers, dubbed aging clocks, designed to measure the rate of aging that could be applied to measure treatment efficacy in clinical...
BioCentury | Jul 22, 2020
Product Development

Pharma survey: COVID-19 foreshadows a change in how business is done

As pharmas grapple with how to return to work, employees are being given the upper hand in deciding when and how to do so. The result could preface a transformation to a semi-virtual office structure,...
BioCentury | Jul 22, 2020
Emerging Company Profile

Jnana goes after metabolism-mediating proteins, gains Roche as partner

Jnana is developing small molecules against a relatively untapped class of proteins -- solute carriers -- to modulate cell metabolism. On Tuesday, the biotech closed its first deal with a large biopharma, partnering with Roche...
Items per page:
1 - 10 of 6276